INTRODUCTION
============

The provision of health care is quite complex and requires the necessary balance between benefits and risks that accompany the whole process, to provide people the most complete well-being[@B10]. Patient safety, understood as reduction of the risk of unnecessary damage associated with care, has been considered a priority attribute of the health systems quality throughout the world[@B10] ^,^ [@B17]. In the context of primary health care, inappropriate correlation between diagnosis and prescribed treatment and misuse of medicines and problems of communication between physicians and patients are the main causes of adverse events[@B19].

The use of multiple medications, or polypharmacy, is increasingly common in clinical practice, particularly in people over 65 years old. This growth is related to multiple factors, such as increased life expectancy and the consequent growth in the prevalence of multimorbidity, the enhanced availability of drug treatments and guidelines that recommend the use of more than one drug in the management of several health conditions, such as hypertension and *diabetes mellitus* [@B7] ^,^ [@B15]. The optimized association of medicines, prescribed according to the best available evidence, can heal, minimize damage, increase longevity, and improve quality of life[@B6]. However, some therapies are inadequate and may cause adverse reactions and drug interactions[@B16].

One of the challenges in discussing polypharmacy and the associated medication safety is the absence of a universally accepted polypharmacy definition[@B7] ^,^ [@B21]. Most of the concepts identified by Bushardt et al.[@B6] relate the term to exacerbated and inappropriate use of medicines. The reasons that explain this practice are treatments not based on evidence; the adoption of combinations with potential drug interactions; the pharmacological treatment of the side effects of other medicines; and the simultaneous prescription by multiple doctors, without the necessary therapeutic conciliation for the patient.

The inappropriate drug therapy is a serious problem for health systems, being recognized as a costly practice[@B6]. According to the World Health Organization[@B28], about 50% of patients with chronic diseases do not adhere to pharmacological treatments, 4% to 5% of the hospital admissions occur because of preventable adverse events, and about 30% of emergency consultations are generated by medicine-related problems, many of them preventable.

Adverse drug events (ADE) are a common and costly complication in health care, representing the fifth cause of death in the United States[@B5]. The age of the patient and polypharmacy are factors associated with the higher number of doctor's appointments and the occurrence of ADE[@B5]. Avoiding the use of unsuitable and high-risk medicines is an important and effective strategy to reduce the problems related to drug treatment, especially in older adults. However, there are important gaps in the knowledge about this phenomenon, and the best evidence come from hospital environments[@B28].

Few studies have assessed polypharmacy in the context of primary health care and in public health systems[@B28]. Also, the scientific evidence of drug effectiveness come from randomized clinical trials, excluding elderly, people with comorbidities, and polypharmacy[@B13]. Thus, most of the articles published in the literature do not provide information directly relevant to the people who need drug associations. Studies on these events in the real world are especially important for a better understanding of the challenges in providing quality health care[@B25].

The *Pesquisa Nacional sobre Acesso, Utilização e Promoção do Uso Racional de Medicamentos* -- *Serviços, 2015* (PNAUM -- National Survey on Access, Use and Promotion of Rational Use of Medicines -- Services, 2015) aimed to characterize the organization of pharmaceutical services in primary health care of the Brazilian Unified Health System (SUS), to promote access and rational use of medicines, as well as identify and discuss factors that interfere in the consolidation of pharmaceutical services in municipalities. In this context, this study, part of PNAUM -- Services, aims to characterize the polypharmacy in patients of the SUS primary health care and to identify its associated factors, to provide subsidies for the improvement of health care in Brazil.

METHODS
=======

This article is part of PNAUM, a cross-sectional, exploratory, and evaluative study, consisting of an information gathering in a representative sample of cities, primary health care services, patients, physicians, and drug dispensers in the five regions of Brazil. The sampling plan considered the various study populations and estimated the sample sizes for each of these populations[@B1]. For each region, 120 cities, 300 health services, and 1,800 patients were sampled. The total sample of patients (9,000) was estimated considering the possibility of up to 20% loss. Patients were interviewed in primary health care services, with a specific structured questionnaire. After the training of the interviewers, a pretest was carried out, involving cities with different population sizes to detect opportunities for improving and to validate the questionnaires. The data were collected from July 2014 to May 2015.

Respondents were asked about the knowledge of chronic diseases diagnosed by a health professional; about emergency care and hospitalization in the 12 months preceding the interview; and about physical activity (frequency in the three previous months), smoking (frequency and quantity of cigarettes), and alcohol use (occurrence, frequency, and number of doses). Regarding the use of medicines, all medicines used in 30 days prior to the interview were registered, according to self-report. To ensure greater accuracy, patients were requested to hand in the prescriptions and/or packages of medicines in use, when available. The subjects were divided into three strata, according to the number of medicines used: one, two to four, and five or more medicines. The variable of interest was polypharmacy, defined as the use of five or more medicines. The medicines were classified according to the fifth level of the Anatomical Therapeutic Chemical index (ATC)[@B29] and described using the *Denominação Comum Brasileira* (DCB -- Brazilian Common Name). The Beers criteria was used to identify the use of potentially inappropriate medications for older adults in the population of the study[@B3].

The association between polypharmacy and sociodemographic variables (gender, age, marital status, educational level, economic class, and having health insurance), lifestyle (alcohol consumption, smoking, physical activity practice), and indicators of health conditions (self-perception of health, number and main chronic diseases self-reported, emergency care and hospitalization) was assessed. These variables were included in the study by their epidemiologic importance and for being associated with polypharmacy in several pharmacoepidemiologic studies[@B4] ^,^ [@B8] ^,^ [@B14] ^,^ [@B21].

Absolute and relative frequencies were used to describe the variables, using the program R® version 3.2.1, with the *survey* package[^a^](#fna){ref-type="fn"}. For group comparison, the Pearson's Chi-square test with Rao-Scott correction was adopted, considering a significance level of 5%. The association between polypharmacy and explanatory variables was evaluated by logistic regression model. Univariate models were used to select variables to the multiple model, being eligible those with p-value lower than or equal to 0.20. The selected variables in the univariate models were included in the multiple model. The *backward* method was adopted to obtain the final model, where the variables with p-value lower than 0.05 remained. The adjustment quality was verified by Hosmer-Lemeshow test.

The research was approved by the National Research Ethics Committee (CONEP), under Opinion no. 398,131/2013. All the interviews were preceded by the clarification of the research's goals to the respondent and by the signature of the informed consent form.

RESULTS
=======

Interviews were carried out with 8,803 patients in primary health care services of 272 Brazilian cities, 97.8% of the planned sample. Of these, 6,511 used at least one medicine. Polypharmacy (use of five drugs or more) was identified in 9.4% (95%CI 7.8--12.0) of medicine users. The majority of polypharmacy patients were female (79.9%, 95%CI 75.2--83.9), aged between 45 and 64 years (54.8%, 95%CI 49--60.5), married or in common-law marriage (64.6%, 95%CI 58.5--70.3), with some elementary school (54.7%, 95%CI 47.1--62.1%), economic class C (54.0%, 95%CI 48.7--59.3), lived in the South region (49.5% CI95% 34.4--61.0), and without health insurance (83.0%, 95%CI 75.5--88.5). Among those who were on polypharmacy, 32.9% (95%CI 28.2--38.0) were older adults above 65 years old ([Table 1](#t1){ref-type="table"}). The prevalence of polypharmacy in this group was 18.1% (95%CI 13.6--22.8%).

Table 1Socioeconomic characteristics of medicine users in the SUS primary health care. Nacional Survey on Access, Use and Promotion of Rational Use of Medicines - Services, 2015.VariableNumber of medicinesp1 (n = 2,561)2--4 (n = 3,340)5 or more (n = 610)n\*% (95%CI)n\*% (95%CI)n\*% (95%CI)Gender      0.146Female1,92274.7 (71.8--77.5)2,61076.7 (74.2--79.0)49279.9 (75.2--83.9) Male63925.3 (22.5--28.2)73023.3 (21.0--25.8)11820.1 (16.1--24.8) Age (years)      \< 0.00118--441,54158.8 (55.9--61.7)1.26635.7 (32.2--39.2)6412.3 (8.8--17.0) 45--6474630.7 (28.2--33.3)1.41443.5 (41.3--45.8)33954.8 (49.0--60.5) ≥ 6524010.4 (8.6--12.6)64020.8 (18.1--23.9)20732.9 (28.2--38.0) Marital status      \< 0.001Married/commom-law marriage1,60864.2 (61.5--66.9)2.05866.4 (64.1--68.7)35064.6 (58.5--70.3) Single68624.5 (22.0--27.2)71817.2 (15.5--19.0)709.1 (6.7--12.2) Others26711.3 (9.6--13.2)56416.3 (14.5--18.3)19026,3 (21.2--32.1) Educational level      \< 0.001Illiterate1878.4 (6.7--10.5)34911.9 (9.1--15.5)11218.5 (13.4--24.9) Some elementary or middle school85737,9 (34,6--41,3)1,34444.7 (40.2--49.2)30954.7 (47.1--62.1) Elementary or middle school34813.7 (10.9--17.2)41612.1 (9.9--14.6)7110.9 (7.6--15.3) High school96433.0 (30.1--36.0)99325.5 (22.4--28.9)9613.3 (9.8--17.8) Higher education2056.9 (5.5--8.7)2385.8 (4.7--7.2)222.6 (1.5--4.4) Economic class      0.844A or B44316.0 (13.2--19.2)53214.7 (12.2--17.7)9714.1 (9.8--19.7) C1,48854.6 (50.7--58.4)1,95454.5 (50.6--58.4)34854.0 (48.7--59.3) D or F62729.5 (24.7--34.7)85330.7 (25.6--36.4)16531.9 (25.0--39.7) Country region      \< 0.001North4916.2 (4.7--8.2)5224.7 (3.5--6.3)261.2 (0.7--2.3) Northeast48329.4 (21.5--38.6)62129.9 (21.5--39.8)7522.1 (13.8--33.5) Midwest5077.1 (5.3--9.6)4614.4 (2.9--6.7)773.5 (1.6--7.5) Southeast57136.6 (28.3--45.7)69432.6 (23.4--43.3)11927.2 (18.1--38.9) South49420.7 (16.2--26.1)89128.4 (20.2--38.4)27545.9 (34.4--61.0) Has health insurance (yes)2159.0 (6.6--12.1)3009.5 (6.7--13.3)8917.0 (11.5--24.5)0.001[^3][^4]

Regarding the self-reported lifestyle and health characteristics, 5.9% (95%CI 3.8--9.1) of patients on polypharmacy consumed alcohol more than once per month, 14.7% (95%CI 10.6--20.1) were smokers, and 29.6% (95%CI 24.7--35.0) practiced physical exercise or sports in the three months preceding the interview ([Table 2](#t2){ref-type="table"}). Most polypharmacy patients classified their health as neither bad/nor good (51.1%, 95%CI 45.3--56.9) and reported having two or more chronic conditions (95.1%, 95%CI 92.1--97.0). The main reported diseases were hypertension (84.3%, 95%CI 79.9--87.9), dyslipidemia (57.8%, 95%CI 51.8--63.6), arthritis, arthrosis, or rheumatism (51.3%, 95%CI 44.8--57.7), and depression (47.3%, 95%CI 40.9--53.9), and *diabetes mellitus* (41.6%, 95%CI 36.6--46.8). Among the 25 most used medicines by polypharmacy patients, 13 (52.0%) belong to group C of the ATC, having action on the cardiovascular system. The most used drugs were simvastatin, losartan, and omeprazole ([Table 3](#t3){ref-type="table"}). Among the most used medicines, we highlight amitriptyline, clonazepam, diazepam, fluoxetine, and ibuprofen, belonging to the list of potentially inappropriate items for use in older adults, according to Beers criteria[@B3].

Table 2Lifestyle characteristics and health condition indicators of patients attended by SUS primary health care. National Survey on Access, Use and Promotion of Rational Use of Medicines -- Services, 2015.VariableNumber of Medicinesp1 (n = 2,561)2--4 (n = 3,340)5 or more (n = 610)n^a^% (95%CI)n^a^% (95%CI)n^a^% (95%CI)Alcohol use (yes)^b^33912.9 (11.0--15.1)3439.4 (7.9--11.1)405.9 (3.8--9.1)\< 0.001Smoking (yes)31913.2 (11.6--15.0)40513.4 (11.5--15.5)8714.7 (10.6--20.1)0.783Practice of physical activity (yes)^c^66223.6 (20.5--27.0)92427.9 (24.0--32.2)18429.6 (24.7--35.0)0.007Self-perception of health      \< 0.001Very good/good1,64563.0 (59.2--66.5)1,61348.5 (44.8--52.2)17325.7 (21.8--30.2) Neither bad/nor good77731.7 (29.2--34.3)1,38841.9 (39.0--44.9)30751.1 (45.3--56.9) Bad/very bad1355.4 (3.8--7.5)3349.6 (8.1--11.3)12923.2 (18.5--28.6) Number of chronic diseases      \< 0.001None1,03639.0 (36.0--42.2)55024.8 (22.1--27.7)81.0 (0.4--2.5) One84036.5 (33.4--39.7)79224.8 (22.1--27.7)3027.2 (25.5--29.1) Two or more59524.5 (22.1--27.0)1,84660.6 (55.9--65.0)53295.1 (92.1--97.0) Main chronic diseases      \< 0.001Hypertension64228.1 (25.1--31.4)1,78756.6 (51.6--61.4)51084.3 (79.9--87.9) Dyslipidemia36714.4 (12.5--16.6)1,03631.6 (28.5--34.9)33857.8 (51.8--63.6) Arthritis, arthrosis, or rheumatism29312.4 (10.4--14.6)89626.5 (23.2--30.1)30651.3 (44.8--57.7) Depression28112.2 (10.5--14.2)78424.5 (21.5--27.9)27747.3 (40.9--53.9) *Diabetes mellitus*1545.4 (4.5--6.5)65321.1 (17.6--25.0)27041.6 (36.6--46.8) Heart diseases993.4 (2.4--4.7)3009.9 (8.1--12.1)19833.3 (27.0--40.3) Chronic pulmonary disease2108.4 (6.9--10.1)40110.7 (9.0--12.6)12118.5 (14.4--23.5) Stroke291.4 (0.8--2.2)1113.3 (2.4--4.4)608.7 (6.2--12.1) Other diseases39615.1 (12.5--18.2)76023.7 (19.7--28.3)22338.7 (31.8--46.2) Emergency care (yes)^d^55019.3 (16.8--22.1)1,00426.1 (22.9--29.6)23639.4 (34.0--45.2)\< 0.001Hospitalization (yes)^d^2037.9 (6.5--9.5)38310.8 (8.8--13.2)11319.9 (15.4--25.3)\< 0.001[^5][^6][^7][^8][^9]

Table 3Most used medicines by polypharmacy patientsa of primary health care services, according the *Anatomical Therapeutic Chemical Classification Index*. National Survey on Access, Use and Promotion of Rational Use of Medicines -- Services, 2015.MedicinesATC Code (5^th^ level)^b^n^c^% (95%CI)SimvastatinC10AA0122435.7 (29.9--42.0)LosartanC09CA0121334.0 (26.9--41.8)OmeprazoleA02BC0120033.6 (28.3--39.4)Acetylsalicylic acidN02BA0117526.5 (20.3--33.7)MetforminA10BA0216124.8 (18.1--33.0)HydrochlorothiazideC03AA0315923.5 (16.8--31.9)EnalaprilC09AA0210115.8 (10.9--22.3)AtenololC07AB0310115.0 (10.3--21.5)Captopril+diureticC09BA016512.2 (7.0--20.5)Fluoxetine^d^N06AB036412.2 (9.3--15.9)GlibenclamideA10BB016711.4 (7.7--16.5)CaptoprilC09AA016111.3 (8.0--15.7)Clonazepam^d^N03AE016011.2 (8.9--13.9)DipyroneN02BB025010.0 (6.5--15.2)Ibuprofen^d^C01EB16529.7 (7.1--13.2)PropranololC07AA05528.8 (6.2--12.5)ParacetamolN02BE01588.7 (6.6--11.3)FurosemideC03CA01558.7 (6.8--11.0)AmlodipineC08CA01648.5 (5.6--12.8)Losartan+diureticC09DA01418.3 (4.0--16.3)Diazepam^d^N05BA01407.4 (3.9--13.6)DiclofenacM01AB05306.8 (4.6--10.1)Amitriptyline^d^N06AA09486.6 (4.5--9.7)Metformin+sulfonylureaA10BD02246.0 (2.0--17.1)Atenolol+thiazidesC07BB03335.3 (2.4--11.5)[^10][^11][^12][^13][^14][^15]

The results of univariate and multiple logistic models for the polypharmacy predictors are presented in [Table 4](#t4){ref-type="table"}. Individuals with health insurance were 1.6 times more likely to be in polypharmacy than those without it. Polypharmacy was significantly associated with age, being higher in older adults over 65 years old (OR 1.95 for people aged between 45 and 64 years old and OR 2.43 for the age group of 65 years old or more). There was association between polypharmacy and self-perception of health, and this association was inversely proportional to the worsening of self-perception (neither bad nor good OR 1.82; 95%CI 1.40--2.38; bad/very bad OR 2.91; 95%CI 1.93--4.38), to the report of having emergency health care (OR 1.59; 95%CI 1.19--2.11) and to having chronic diseases, with the highest association in hypertensive patients (OR 3.49; 95%CI 2.43--5.21). The association between the Country regions and polypharmacy was variable, and living in the South region showed higher association (5.8 times higher than in the North).

Table 4Associated factors (odds ratio) with polypharmacy among patients of SUS primary health care services. National Survey on Access, Use and Promotion of Rational Use of Medicines -- Services, 2015.VariableUnivariatepMultiple^a^pOR95%CIOR95%CIIntercept------0.0040.002--0.008\< 0.001Sex      Male------   Female1.2660.954--1.6800.103   Age (years)      18--44------------45--645.2793.499--7.964\< 0.0011.9461.275--2.970\< 0.001≥ 657.3164.904--10.914\< 0.0012.4281.541--3.825\< 0.001Education level      Higher education------   High school1.1310.603--2.1210.702   Elementary or middle school2.0691.051--4.0710.036   Some elementary or middle school3.1761.768--5.706\< 0.001   Illiterate4.2962.177--8.474\< 0.001   Marital status      Single------   Married/common-law marriage2.2021.572--3.084\< 0.001   Others4.1192.804--6.049\< 0.001   Economic class      A or B------   C1.0720.764--1.5040.686   D or E1.1430.717--1.8230.574   Has health insuranceNo------------Yes2.0041.582--2.538\< 0.0011.6021.125--2.2780.009HypertensionNo------------Yes6.6334.765--9.234\< 0.0013.4962.345--5.211\< 0.001*Diabetes mellitus*     No------------Yes4.1773.226--5.408\< 0.0012.2971.753--3.009\< 0.001DepressionNo------------Yes3.7253.002--4.623\< 0.0012.3811.862--3.044\< 0.001Arthritis      No------------Yes4.0523.179--5.163\< 0.0011.7361.314--2.295\< 0.001Self-perception of healthGood/Very good------------Neither good nor bad2.8712.289--3.602\< 0.0011.8231.400--2.375\< 0.001Bad/Very bad6.2444.525--8.615\< 0.0012.9121.935--4.380\< 0.001Country region      North------------Midwest2.8201.359--5.8510.0052.3041.096--4.8440.027Northeast3.5421.814--6.913\< 0.0012.7671.358--5.6380.005Southeast3.6481.894--7.024\< 0.0012.6211.266--5.4300.010South8.8294.867--16.015\< 0.0015.8153.133--10.794\< 0.001Emergency careNo------------Yes2.1441.688--2.722\< 0.0011.5921.198--2.114\< 0.001Hospitalization      No------------Yes2.3461.718--3.204\< 0.001   [^16][^17]

DISCUSSION
==========

The prevalence of polypharmacy observed in this study (9.4%, 95%CI 7.8--12.0) was similar to that of primary health care in Germany (10.0%)[@B12] and lower than the 20.8% in adults attended by primary health care in Scotland[@B13]. Polypharmacy in people over 65 years old (18.1%) was higher than the 11.0% in older adults from areas covered by the *Estratégia Saúde da Família* (ESF -- Family Health Strategy) in Recife, state of Pernambuco[@B21], but lower than that found in other studies: 28.0% in the older adults in Goiânia[@B27], 32.7% among retirees in Rio de Janeiro[@B24], 36% in the older adults in the city of São Paulo[@B8], and 35.8% in North-American older adults[@B22].

Studies on polypharmacy in primary health care, including the general population, are scarce[@B12] ^,^ [@B13] ^,^ [@B19]. Considering the process of population aging and evidence about the relationship between increasing age and number of prescription drugs, professionals must ensure the quality of pharmacotherapy in the health care process, avoiding the excessive use of multiple medicines[@B7] ^,^ [@B13] ^,^ [@B15]. Polypharmacy has been linked to negative health outcomes; increased morbidity and mortality; reduction of the quality of life, especially in older adults; and increased costs of care, with impact to patients and health care systems[@B7].

In recent years, geriatric polypharmacy has significantly increased. This group typically has a high comorbidity index, high risk for prescription of potentially inappropriate medicines, and are more susceptible to loss of doses or administration errors, which may impair adherence to treatment[@B7] ^,^ [@B20]. In addition, they often present a compromised nutritional status and pharmacokinetic and pharmacodynamic changes inherent to the aging process. These characteristics explain the greater vulnerability of older adults to the occurrence of adverse events, reduction of therapeutic efficacy, and increased risk of drug interactions[@B8] ^,^ [@B20] ^,^ [@B21] ^,^ [@B27]. Observational studies have shown a strong relationship between the use of potentially inappropriate medications and adverse health outcomes, such as ADE (gastrointestinal bleeding, sedation, delirium, falls and fractures), hospitalization, and death[@B2].

Although most studies investigated polypharmacy in older adults, this study showed a significant association between the age group of 45 to 64 years old and the use of five or more drugs. These data need to be better understood to guide public policies and qualify the assistance in primary health care. The model "one disease -- one drug therapy" is an inadequate approach in face of the epidemic of medicine use in the 21^st^ century. As pointed out by Bjerrum et al.[@B4], the implementation of information strategies for general practitioners on prescribing in primary care can improve this practice and reduce polypharmacy, qualifying health care.

The variables gender, economic class, marital status, and education level were less relevant in determining the consumption of multiple medicines in SUS primary health care. Loyola Filho, Uchoa, and Lima-Costa[@B14] highlighted that only isolated studies have identified a relationship between higher education level, widowhood, and polypharmacy. Regarding sex, most national and international surveys[@B4] ^,^ [@B8] ^,^ [@B9] ^,^ [@B14] ^,^ [@B27] indicate that women seek more health services and that conditions inherent to their reproductive role, such as pregnancy and contraception, may explain the increased use of medicines[@B14] ^,^ [@B15]. However, this study did not observe association between gender and polypharmacy. Consistent with this result is the study of O'Dwyer et al.[@B22] in a population over 40 years old in Ireland, which also found no association between polypharmacy and female sex.

Similar to other national studies[@B8] ^,^ [@B21], individuals with health insurance presented a higher chance of polypharmacy. They have greater access to appointments with medical specialists, expanding the variety of prescriptions[@B2] ^,^ [@B8]. According to Neves et al.[@B21], general practitioners of the Family Health Strategy normally prescribe items from SUS essential list, to enable the free drug supply. This practice reduces the amplitude of the therapeutic arsenal and, consequently, the average number of medicines prescribed per patient.

The self-assessment of health as regular and bad/very bad, observed by other studies[@B8] ^,^ [@B14] ^,^ [@B15] ^,^ [@B21], showed positive association with polypharmacy. According to Carvalho et al.[@B8], these findings are consistent because the connection between health problems and medicine use is obvious. These results are reinforced by the association also verified with the emergency medical service, which may be related to a worse health condition. Furthermore, Mira et al.[@B19] identified that 5% of medication errors in polypharmacy patients had serious consequences, requiring emergency care or hospitalization.

The association between self-report of hypertension, *diabetes mellitus*, depression, rheumatic diseases, and polypharmacy is in line with other national and international studies[@B4] ^,^ [@B8] ^,^ [@B15] ^,^ [@B24]. These are prevalent conditions in the Country, especially in older adults, whose control and treatment require the use of medicines. There is consistency between the 25 most used medicines by polypharmacy individuals and self-reported diseases. Hypertension, corroborating other studies[@B8] ^,^ [@B21], was the most frequent chronic disease and presented the most intense association with polypharmacy.

The higher prevalence of medicines for the cardiovascular system (ATC group C) in the polypharmacy population corroborates with Charlesworth et al.[@B9], who observed a relationship between the classes of antihypertensives, statins, and antidiabetics and the increase in the prevalence of drug use in American older adults. Qato et al.[@B23] observed a statistically significant increase in the prescription of statins in the United States of America, reaching 46.2% of people over 65 years old, in 2011. Evidence on the clinical use of statins are controversial, with some studies showing its usefulness in reducing morbidity and mortality and others showing its potential damage[@B11].

The high use of omeprazole in this study may be explained, according to Carvalho et al.[@B8], by the prophylactic and not always rational prescription of drugs for reducing gastric acidity. Often, an adverse reaction can be interpreted as new clinical entity, being treated with new medication, which constitutes an iatrogenic cascade[@B8]. Bjerrum et al.[@B4] point out that some authors consider polypharmacy an "uncontrolled experiment," because most individuals has a unique combination of medicines and, therefore, require individualized care and therapeutic conciliation.

Among the most used medicines by the polypharmacy patients, we highlight five items (amitriptyline, clonazepam, diazepam, fluoxetine, and ibuprofen), which belong to the list of potentially inappropriate medications for use in older adults, according to Beers criteria[@B3]. These results are very relevant when considering that the age group above 65 years old was associated with the greatest chance of polypharmacy within the primary health care of SUS. The Beers criteria is an important measure of quality of health care in older adults, and it should be incorporated into electronic record systems to support the prescription process and to identify situations in which non-pharmacological alternatives would be more appropriated[@B2] ^,^ [@B3].

The polypharmacy varied according to Brazilian regions, with greater association in the South and Southeast. These results can be explained by the characteristics of the population sampled, because individuals of these regions showed higher prevalence of comorbidities. In addition, the states of those regions have a higher health care insurance coverage, variable predictive of polypharmacy in this study[@B18].

As Rozenfeld et al.[@B24] point out, polypharmacy is not always a preventable event. Chronic diseases of high prevalence, such as hypertension and *diabetes mellitus*, are typically handled by association of medicines. The review of drugs and the potential deprescription should be evaluated mainly by physicians or pharmacists, to customize the treatment in people with multimorbidity or specific vulnerability. Also, the monitoring for the potential occurrence of drug interactions is important[@B13]. According to Secoli et al.[@B26], the evaluation of multiple therapeutic regimens, especially in older adults, allows the identification of associations with potential drug interactions and their suspension, to minimize the damage and qualify the medicine use. Protocols and guidelines for the management of the most prevalent chronic diseases must contain, in addition to the treatment indications, recommendations about situations where deprescription can be adopted.

There is evidence that prescribers' education, with emphasis on stimulating preventive practices, impacts adherence to therapy and the quality of medicines use[@B25]. Mira et al.[@B19] found that only 32.5% of patients attended by the Spanish primary health care were asked by physicians about drugs prescribed by other health professionals. In this study, the medication errors were associated with: feeling of not being listened to, loss of confidence in the physician, occurrence of simultaneous prescriptions by several medical specialists, and incongruent information between different health professionals.

Pharmaceutical care services, with appointments to develop care plans, to solve problems related to medicines, and to provide timely follow-up, focusing on the acquisition of skills for the co-responsibility, can improve adherence to drug therapy and, consequently, clinical outcomes. The adoption of strategies for the self-registration of all medicines used by patients, including medicinal plants, non-prescription drugs, and dietary supplements, may contribute to the clinical history improvement, reducing the memory bias[@B6].

This study has some limitations. Because it is the first nationwide study on polypharmacy in patients of public health services, there are methodological differences and diversity between the populations of the studies used to data discussion, which restricts the direct comparison. Another limitation refers to the polypharmacy concept adopted, considered only as the concomitant use of multiple medicines. We did not verify the reasons for drug prescription, to assess the appropriateness of the use of each medicine. In addition, the data presented may be underestimated by memory constraints, because medicines and diseases were self-reported by patients. Because it is a cross-sectional study, it is not possible to establish the temporality of the associated factors.

Despite the presented limitations, the results showed a high rate of polypharmacy, especially in the elderly population, which needs to be better understood by managers and multidisciplinary health teams. Reducing avoidable complications and medication errors are increasing needs and should promote the adoption of safe practices, based on scientific evidence. According to Bjerrum et al.[@B4], programs designed to reduce problems associated with polypharmacy are more effective when developed for subgroups of patients with increased risk. In the health care process, the establishment of co-responsibility and solidarity links with patients and their families contribute to the strengthening of the patient's safety[@B17].

In conclusion, polypharmacy is a reality in the population attended by the SUS primary health care. The recent epidemiological changes, with the increase in life expectancy and, consequently, chronic diseases, has changed the perspective on the use of multiple medicines in health care. Considering the important role of the drug public supply in Brazil, this study provides subsidies for the improvement of prescribing practices and use of medicines. Activities to increase drug safety in sub-populations with a greater chance of polypharmacy have the potential to reduce preventable adverse events, especially in older adults.

The number of drugs prescribed should consider the real needs of each patient and the balance between potential benefits and risks. The main challenge to qualify health care is to ensure that the prescription of multiple drugs is appropriate and safe. Regular evaluation of the therapeutic regimens, focusing on adherence, adjustment to individual preferences, and risk identification can minimize the damage and maximize the benefits. Continued professional training, multidisciplinary team work, and population education are important strategies to qualify the use of medicines and strengthen the *Política Nacional de Segurança do Paciente* (PNSP -- National Policy for Patient Safety).

T. Lumley "survey: analysis of complex survey samples". R package version 3.30. Vienna: The R Foundation; 2014.
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